Aronora is Revolutionizing Blood Clot Treatment with Groundbreaking Innovations
Presentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation